Pacira Pharma Shares Sink as Co. Announces EXPAREL Phase 3 Trial Does Not Meet Primary Endpoint

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX ) today announced results from its second pivotal, Phase 3 clinical trial assessing the safety and efficacy of EXPAREL^® (bupivacaine liposome injectable suspension) in intercostal nerve block for posterolateral thoracotomy. The study did not achieve its primary endpoint of a reduction of cumulative pain scores over 72 hours. The